


Evidence collections

In our evidence collections we bring together a curated selection of some of our most topical and most used resources. To see a full list of all resources, go to [search all resources](#).

Four additional collections have been created in collaboration with Cochrane. [View the Cochrane – Evidence Aid collections](#)

We have also collated a list of external [online collections of research for the humanitarian sector](#).



Case study

Innovative concepts to communicate science

DURING COVID-19

Contributor
Evidence Aid

Country of implementation
Global

Start date of the initiative
February 2020

Track
Science communication by researchers

Target audience
Decision-makers

Website
<https://evidenceaid.org/>

Evidence Aid: COVID-19 evidence summaries collection

Summary of the initiative

This online platform run by Evidence Aid provides plain language summaries of systematic reviews on research and evidence-based interventions for prevention and treatment of the coronavirus disease (COVID-19). It complements Evidence Aid's regular activities aimed at providing decision-makers with evidence on how to prepare for and respond to emergencies.

The collection of summaries of high-quality systematic reviews provides policy analysts and decision-makers in the health sector with easy access to the latest evidence on what works and what might not work in the global response to COVID-19.

The initiative operates on five channels: a project website,ⁱ Facebook,ⁱⁱ Instagram,ⁱⁱⁱ LinkedIn,^{iv} and Twitter^v. The team publishes its summaries on the project website, with an emphasis

on adding reviews that are up-to-date and likely to be most relevant to decision-makers. The reach is amplified by sharing the content across the other outlets. The summaries are available in eight languages: Arabic, Chinese, English, French, German, Italian, Portuguese and Spanish.

An international team of volunteers who have a wide variety of backgrounds, and include medical students, information specialists, health care practitioners and academic researchers, including professors in various disciplines engage in the distillation of systematic reviews into plain language summaries. To date, they have reviewed more than 900 systematic reviews from which over 580 summaries have been produced.

Image above: screenshot of the Evidence Aid homepage. Copyright and credit: Evidence Aid.

Context and relevance of the project

Evidence Aid is an international platform that provides access to lay summaries of research relevant to disasters and other humanitarian emergencies. When the COVID-19 pandemic began, their focus shifted to support the pandemic response.

The team established a Special Collection of COVID-19-related evidence on its website starting in March 2020. Team members have been assisting decision-makers to cope with the vast number of scientific reports on COVID-19 by collating and summarizing scientific information in one place, and promoting it through direct emails and social media, including regular Tweets to their nearly 10 000 followers.

Summary of the analysis



Innovation factors

The COVID-19 pandemic has produced an immense amount of research investigating the transmission modes, consequences, preventive measures and risks of infection. Systematic reviews are the gold standard for evidence synthesis, systematically summarizing and assessing the body of research for a pre-defined research question. However, they often use subject-specific terminology and are written in a very technical manner. This makes their content and conclusions less accessible for people with different professional backgrounds or lay readers. In addition, the reviews, like the studies they include, are often scattered across multiple databases, journals and websites requiring advanced scientific search skills, sometimes expensive database subscriptions and considerable time to search through all the evidence.

Evidence Aid produces short summaries of about half a page for the latest systematic reviews on COVID-19. The summaries are written in plain language and follow a structured format focusing on:

- what was being researched;
- what was found as a result of the review;
- what implications the results have; and
- any other considerations taken during the search such as location of the original studies, etc.

The project website includes summaries of systematic reviews in areas such as diagnosis, prognosis and epidemiology of COVID-19 as well as public health interventions that are relevant to the pandemic response and recovery. While most evidence synthesis work has focused on the rapidly evolving research on COVID-19, the Evidence Aid team also searches for reviews of relevant pre-pandemic research which can be used to make decisions about COVID-19 and its effects.

This allows decision-makers and other interested audiences to gain a rapid overview of the content and conclusions of the latest, best available evidence on COVID-19-related topics. During a time in which evidence-informed decisions are crucial but the amount of emerging evidence is overwhelming, the Evidence Aid platform makes a significant contribution to science translation.

The summaries are innovative in drawing on feedback from decision-makers in different levels of government, nongovernmental, and humanitarian organizations.

Accuracy of scientific information


As sources, the team uses:

- systemic reviews of emerging research;
- pre-pandemic reviews of relevant interventions, such as those used to prevent and treat other coronaviruses;
- reviews on other health conditions that might be impacted by the consequences of COVID-19, such as those relating to the use of telehealth; and
- reviews that may be important for the recovery period after the pandemic, including those on the mental health impact of the pandemic measures.

These are found from regular searches of the health care literature, using databases such as PubMed.

The summaries are freely accessible online with links to the original systematic reviews for transparency and to facilitate the user's information search.





A screenshot of the Evidence Aid homepage. Copyright and credit: Evidence Aid.



Impact on knowledge, attitudes and behaviour of the target audience

Impact analytics include:

- 500 000 unique visitors to the Evidence Aid website worldwide between March 2020 and December 2021, a massive increase from the less than 40 000 who accessed the website in 2019;
- 10 000 followers on the project's Twitter account;
- 860 members on the Facebook group;
- 820 followers on Facebook page;
- 613 followers on LinkedIn; and
- 145 followers on Instagram.


A recent study by researchers at McMaster University in Canada interviewed more than 30 Evidence Aid users working in parts of the world particularly affected by humanitarian crises. The findings showed that the respondents found the resources to be useful, accessible and credible.

As a follow-up, the project team conducted a mixed-methods study examining the views and experiences of people making decisions about the response to COVID-19 of using the COVID-19 evidence summaries to inform their decision-making. Preliminary findings indicate that they found the collection relevant, easy-to-understand, specific and concise. The team expects to publish the results from the study and use them for quality improvement.

Gender equality, equity and human rights considerations

The project promotes information-equity and human rights by providing access to reliable and accurate health information in plain language for free. This enables users of any literacy level to make evidence-informed decisions during the pandemic.

The summaries are available in multiple languages to promote multilingualism.





Challenges, solutions, and limitations

The project relies on volunteers who struggle to keep up with the large number of reviews published every week. The team is soliciting funds to sustain the project by recruiting full-time staff and scaling up the work.


The team believes that the project will have more impact with a suitable promotion strategy as there is suboptimal awareness of its work among decision-makers on a global scale. To overcome this, the team is publishing monthly newsletters, engaging with a wider audience through social media, and recruiting new volunteers and researchers from around the world.

Looking forward

The project team continues to produce evidence summaries and improve the format to respond to the feedback collected. Additionally, team members are collaborating with agencies such as the Pan American Health Organization and the UK Health Security Agency (formerly, Public Health England) to increase outreach and consolidate efforts to support evidence-informed decision-making.

Evidence Aid is also working with the World Health Organization to build a knowledge hub for health emergency and disaster risk management research. This work aims to build a strong evidence base for health and natural disasters.

The team recognizes that currently most resources are focused on COVID-19 research which has deprived other areas of health and social care which now needs to recover, become more resilient and grow.



References

- i. Evidence Aid. Coronavirus (<https://evidenceaid.org/evidence/coronavirus-covid-19/?p=101888&language=en>).
- ii. Evidence Aid Facebook page (<https://www.facebook.com/EvidenceAid/>).
- iii. Evidence Aid Instagram account (<https://www.instagram.com/evidenceaid/>).
- iv. Evidence Aid LinkedIn page (<https://www.linkedin.com/company/evidence-aid/>).
- v. Evidence Aid on Twitter (https://twitter.com/EvidenceAid?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor).

Illustrations by Sam Bradd

Disclaimers

The World Health Organization (WHO) has invited individuals, institutions, governments, non-governmental organizations or other entities to submit case studies of good practices and innovative solutions in the area of communicating public health science during the COVID-19 pandemic through a public call for submission. WHO has selected a few cases based on a pre-defined rating system and makes such publications publicly available on the WHO website (the "Website").

Contributors (authors) are solely responsible for their contributions, and readers are solely responsible for the interpretation of the posted contributions. The views expressed in the posted contributions are those of the authors and do not necessarily reflect those of WHO.

In no event shall WHO be responsible for the accuracy of information contained in the posted contributions and WHO makes no warranties or representations regarding the completeness or accuracy of any content included in the contributions. WHO shall not be held liable for any damages whatsoever arising out of the use of the contributions. WHO reserves the right to make updates and changes to posted content without notice and accepts no liability for any errors or omissions in this regard. WHO accepts no responsibility whatsoever for any inaccurate advice or information that may be contained in the contributions or referred to in sources reached via links or other external references to the content of the contributions.

The contributions may contain links to resources on external websites. WHO is not responsible for the accuracy or content of any external link. The presence of any resource or external link in the contributions does not imply that the resource, or its author or entity, is endorsed or recommended by the WHO. These links are provided for convenience only. The designations employed and the presentation of content in the contributions, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted; the names of proprietary products are distinguished by initial capital letters.

Contributions are for use of the WHO and users of the WHO website. Reproduction or translation of substantial portions of the contributions, or any use other than for educational or other non-commercial purposes, require the prior authorization in writing of the relevant author/contributor.

World Health Organization
20 Avenue Appia CH 1211,
Geneva 27
Switzerland

epi-win@who.int

www.who.int/epi-win



EPI • WIN